当前位置:首页 - 行情中心 - 药石科技(300725) - 财务分析 - 利润表

药石科技

(300725)

  

流通市值:53.37亿  总市值:63.25亿
流通股本:1.68亿   总股本:2.00亿

利润表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、营业总收入377,460,431.511,725,203,986.491,291,461,856.48844,058,257.07
营业收入377,460,431.511,725,203,986.491,291,461,856.48844,058,257.07
二、营业总成本325,204,409.511,487,211,816.481,089,728,764.88705,562,849.81
营业成本216,310,157.43991,669,209.12737,710,733.45475,390,933.61
税金及附加5,103,201.6318,631,576.349,827,456.027,240,481.49
销售费用14,116,09853,206,95441,155,552.0927,093,765.77
管理费用47,045,256.92200,229,764.67148,753,262.64100,879,023.6
研发费用34,513,051.4169,173,650.38132,533,134.9892,468,805.87
财务费用8,116,644.1354,300,661.9719,748,625.72,489,839.47
其中:利息费用15,409,320.0466,095,508.0649,353,765.1632,225,393.71
其中:利息收入4,042,244.0413,438,804.0319,827,500.178,502,297.82
加:公允价值变动收益8,165,644.23-21,326,089.05-55,717,490.98-41,579,248.22
加:投资收益-2,072,743.2811,353,439.9819,891,646.7816,981,528.91
资产处置收益-416,669.74-108,152.76-
资产减值损失(新)-7,748,338.22-37,720,296.35-21,077,163.2-20,584,518.67
信用减值损失(新)1,065,016.77-9,948,425.48-6,785,212.05-2,554,427.26
其他收益1,172,355.33,832,524.22--
营业利润平衡项目0000
四、营业利润52,837,956.8184,599,993.07137,936,719.3990,758,742.02
加:营业外收入2,772,139.0441,060,256.3732,501,420.5430,334,956.18
减:营业外支出5,771.944,285,206.4300,229.95212,921.34
利润总额平衡项目0000
五、利润总额55,604,323.9221,375,043.04170,137,909.98120,880,776.86
减:所得税费用6,118,964.724,014,109.7416,091,654.736,989,792
六、净利润49,485,359.2197,360,933.3154,046,255.25113,890,984.86
持续经营净利润49,485,359.2197,360,933.3154,046,255.25113,890,984.86
归属于母公司股东的净利润49,485,359.2197,360,947.76154,046,269.72113,890,999.33
少数股东损益--14.46-14.47-14.47
(一)基本每股收益0.250.990.770.57
(二)稀释每股收益0.240.980.770.57
八、其他综合收益141,525.361,512,231.522,855,135.083,876,953.12
归属于母公司股东的其他综合收益141,525.361,512,231.522,855,135.083,876,953.12
九、综合收益总额49,626,884.56198,873,164.82156,901,390.33117,767,937.98
归属于母公司股东的综合收益总额49,626,884.56198,873,179.28156,901,404.8117,767,952.45
归属于少数股东的综合收益总额--14.46-14.47-14.47
公告日期2024-04-242024-04-242023-10-312023-08-15
审计意见(境内)标准无保留意见
TOP↑